IL13 and skin basal cell carcinoma: By studying BCC lesions with and without the topical immune modifier imiquimod, Tjiu et al. demonstrated that an environment abundant in Th2 cytokines, such as interleukin (IL)-4, IL-5, IL-10, and IL-13, facilitated BCC progression.